GenSight Biologics S.A. (GSGTF)

OTCMKTS · Delayed Price · Currency is USD
0.2400
-0.0800 (-25.00%)
At close: Dec 31, 2024
-25.00%
Market Cap24.96M
Revenue (ttm)2.72M
Net Income (ttm)-14.50M
Shares Outn/a
EPS (ttm)-0.15
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume4,012
Average Volume1,703
Open0.2500
Previous Close0.3200
Day's Range0.2400 - 0.2500
52-Week Range0.2400 - 0.4800
Beta1.96
RSI28.66
Earnings DateSep 19, 2025

About GenSight Biologics

GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ, a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 16
Stock Exchange OTCMKTS
Ticker Symbol GSGTF
Full Company Profile

Financial Performance

In 2024, GenSight Biologics's revenue was 2.63 million, a decrease of -11.44% compared to the previous year's 2.96 million. Losses were -14.00 million, -46.60% less than in 2023.

Financial numbers in EUR Financial Statements

News

GenSight Biologics Announces Publication on Predictors of Final Visual Outcome in Patients Treated with LUMEVOQ® Gene Therapy

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene thera...

16 days ago - Business Wire

GenSight Biologics Reports Cash Position as of June 30, 2025

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing a...

24 days ago - Business Wire

GenSight Biologics Reaches Agreement with ANSM for Opening of LUMEVOQ® Named Early Access Program (AAC) in France

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing a...

7 weeks ago - Business Wire

GenSight Biologics Announces Approval of All Resolutions Supported by the Board of Directors at the Combined General Meeting of May 13, 2025

PARIS--(BUSINESS WIRE)--Regulatory News: The Combined General Meeting of shareholders of GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on deve...

2 months ago - Business Wire

GenSight Biologics Annual General Meeting on May 13, 2025

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene thera...

3 months ago - Business Wire

GenSight Biologics Announces the Filing of its 2024 Universal Registration Document

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene thera...

4 months ago - Business Wire

GenSight Biologics Reports Cash Position as of March 31, 2025, and Provides Business Update

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing a...

4 months ago - Business Wire

GenSight Biologics Confirms Definitive Full-Year 2024 Consolidated Financial Results Are in Line with Estimates

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene thera...

4 months ago - Business Wire

GenSight Biologics Announces LUMEVOQ® Scientific Updates at NANOS 2025

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies...

4 months ago - Business Wire

GenSight Biologics S.A. reports FY results

5 months ago - Seeking Alpha

GenSight Biologics Reports Estimated Full-Year 2024 Consolidated Financial Results

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene thera...

5 months ago - Business Wire

GenSight Biologics Announces Five-Year Efficacy and Safety Results for LUMEVOQ® Gene Therapy at the Conclusion of the REFLECT Study

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene thera...

6 months ago - Business Wire

GenSight Biologics Reports End-of-Year Cash Position and Provides Business Update

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing a...

6 months ago - Business Wire

GenSight Biologics Announces Publication of 5-Year Outcomes for Patients Treated Unilaterally with LUMEVOQ® Gene Therapy

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene thera...

7 months ago - Business Wire

GenSight Biologics Provides Update on Regulatory Discussions and Financial Situation

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing a...

8 months ago - Business Wire

GenSight Biologics Announces Submission of LUMEVOQ® Dossier to ANSM to Prepare for Restart of Early Access Program in France

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene thera...

9 months ago - Business Wire

GenSight Biologics Announces Publication of Meta-Analyses Showing Better Outcomes for ND4-LHON Patients Treated with LUMEVOQ®

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene thera...

9 months ago - Business Wire

GenSight Biologics Reports Cash Position as of September 30, 2024, and Provides Business Update

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing a...

10 months ago - Business Wire

GenSight Biologics Announces LUMEVOQ® Scientific Updates at AAO 2024

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies...

10 months ago - Business Wire

GenSight Biologics S.A. reports 1H results

11 months ago - Seeking Alpha

GenSight Biologics Reports Interim Financial Results for the First Half of 2024, Provides Business Updates

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene thera...

11 months ago - Business Wire

GenSight Biologics Reports Cash Position as of June 30, 2024, and Provides Business Update

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene thera...

1 year ago - Business Wire

GenSight Biologics Launches Newsletter for Retail Investors

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene thera...

1 year ago - Business Wire

GenSight Biologics Renegotiates Financial Obligations and Provides Operational Updates

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene thera...

1 year ago - Business Wire

GenSight Biologics to Present at Upcoming Medical Conferences and Stakeholder Meetings

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene thera...

1 year ago - Business Wire